Defining the diagnosis of invasive aspergillosis
- PMID: 30408899
- DOI: 10.1080/13693780600823258
Defining the diagnosis of invasive aspergillosis
Abstract
Invasive aspergillosis (IA) is a leading cause of death in severely immunocompromised patients. Delayed diagnosis remains a major impediment to successful treatment of IA. Conventional diagnostic methods based on use of histology and culture remain the cornerstone of diagnosis of IA. However, they have a low yield, and performance of them is frequently precluded in patients with cytopenia and/or underlying comorbidities. In recent years, efforts have been directed toward identifying non-culture-based markers for early, reliable diagnosis of IA by detection of Aspergillus components such as galactomannan (GM), 1,3-β-D-glucan, and DNA. Studies of profoundly neutropenic hematopoietic stem cell transplant recipients on fluconazole prophylaxis have shown high sensitivity (67-100%) and specificity (86-99%) rates for the GM assay. However, the performance of the GM assay in other settings, including pediatric patients, patients receiving mould-active antifungal prophylaxis, patients with GvHD and recipients of solid organ transplants, is suboptimal. Other factors, such as the pretest probability of infection, sequestration of Aspergillus lesions, the patient's immune status, the presence of anti-GM antibodies, antibacterial therapy, and diet, may also affect both the performance and interpretation of the GM assay. A colorimetric assay for the detection of 1,3-β-D-glucan, an integral cell-wall component of most pathogenic fungi, has shown promising sensitivity (55-100%) and specificity (52-100%) in limited studies. Polymerase chain reaction (PCR) analysis of Aspergillus DNA is also a promising method for early detection of IA and other opportunistic fungal infections. The sensitivity of PCR is excellent, but its low level of specificity for invasive infections can be problematic. Multiple unresolved issues accompany the use of PCR for diagnosis of IA, including the sample type, amplification strategy, protocol, and primer selection, and account for the lack of a standardized, commercially available assay. Comparative prospective evaluation of non-culture-based assays would facilitate their incorporation into pre-emptive strategies for the optimal management of IA. Combinations of non-culture-based assays could enhance their performance and broaden the spectrum of detectable fungi. Clearly, there is a need for innovation in this area. Preclinical studies suggest that detection of secondary metabolites for Aspergillus and use of novel immunolabeling approaches to positron emission tomography are potentially new avenues for the development of novel diagnostics. In view of the evolving epidemiology of opportunistic mould infections, developing diagnostic strategies to distinguish between pulmonary aspergillosis and other lung mycoses is another important future research direction.
Similar articles
-
[Comparison of glucan and galactomannan tests with real-time PCR for diagnosis of invasive aspergillosis in a neutropenic rat model].Mikrobiyol Bul. 2010 Jul;44(3):441-52. Mikrobiyol Bul. 2010. PMID: 21063994 Turkish.
-
Serum galactomannan versus a combination of galactomannan and polymerase chain reaction-based Aspergillus DNA detection for early therapy of invasive aspergillosis in high-risk hematological patients: a randomized controlled trial.Clin Infect Dis. 2015 Feb 1;60(3):405-14. doi: 10.1093/cid/ciu833. Epub 2014 Oct 21. Clin Infect Dis. 2015. PMID: 25336623 Clinical Trial.
-
Diagnosis of invasive fungal infections in haematological patients by combined use of galactomannan, 1,3-β-D-glucan, Aspergillus PCR, multifungal DNA-microarray, and Aspergillus azole resistance PCRs in blood and bronchoalveolar lavage samples: results of a prospective multicentre study.Clin Microbiol Infect. 2016 Oct;22(10):862-868. doi: 10.1016/j.cmi.2016.06.021. Epub 2016 Jul 5. Clin Microbiol Infect. 2016. PMID: 27393123
-
Contribution of new diagnostic approaches to antifungal treatment plans in high-risk haematology patients.Clin Microbiol Infect. 2008 May;14 Suppl 4:37-45. doi: 10.1111/j.1469-0691.2008.01980.x. Clin Microbiol Infect. 2008. PMID: 18430128 Review.
-
Aspergillus PCR formidable challenges and progress.Med Mycol. 2009;47 Suppl 1:S241-7. doi: 10.1080/13693780802616823. Epub 2009 Feb 27. Med Mycol. 2009. PMID: 19253138 Review.
Cited by
-
Contribution of the (1-->3)-beta-D-glucan assay for diagnosis of invasive fungal infections.J Clin Microbiol. 2008 Mar;46(3):1009-13. doi: 10.1128/JCM.02091-07. Epub 2007 Dec 26. J Clin Microbiol. 2008. PMID: 18160456 Free PMC article.
-
First report of invasive Aspergillus rhinosinusitis in a critically ill COVID-19 patient affected by acute myeloid leukemia, northeastern Iran.Clin Case Rep. 2021 Oct 4;9(10):e04889. doi: 10.1002/ccr3.4889. eCollection 2021 Oct. Clin Case Rep. 2021. PMID: 34631073 Free PMC article.
-
Clinical Manifestations of Human Exposure to Fungi.J Fungi (Basel). 2023 Mar 21;9(3):381. doi: 10.3390/jof9030381. J Fungi (Basel). 2023. PMID: 36983549 Free PMC article. Review.
-
Targeting UDP-galactopyranose mutases from eukaryotic human pathogens.Curr Pharm Des. 2013;19(14):2561-73. doi: 10.2174/1381612811319140007. Curr Pharm Des. 2013. PMID: 23116395 Free PMC article. Review.
-
Antifungal drug resistance: do molecular methods provide a way forward?Curr Opin Infect Dis. 2009 Dec;22(6):568-73. doi: 10.1097/QCO.0b013e3283321ce5. Curr Opin Infect Dis. 2009. PMID: 19741524 Free PMC article. Review.
LinkOut - more resources
Full Text Sources